Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Atara Biotherapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 134 | 155 | +21 |
| Shares | 99.8M | 99.5M | −302.9K (−0.3%) |
| Value | $777.4M | $376.2M | −$401.3M (−51.6%) |
New holders (40)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (19)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Eminence Capital, LP | 1,323,075 | $10.3M |
| Artal Group S.A. | 1,000,000 | $7.79M |
| Healthcare of Ontario Pension Plan Trust Fund | 616,900 | $4.81M |
| One Fin Capital Management LP | 303,000 | $2.36M |
| M28 Capital Management LP | 269,253 | $2.10M |
| Integral Health Asset Management, LLC | 208,738 | $1.63M |
| Bank of Montreal | 153,799 | $1.09M |
| Sector Gamma AS | 123,713 | $964.0K |
| Trellus Management Company, LLC | 110,000 | $857.0K |
| Jefferies Group LLC | 70,000 | $545.3K |
| Caption Management, LLC | 52,000 | $405.0K |
| DekaBank Deutsche Girozentrale | 31,200 | $231.0K |
| Quantbot Technologies LP | 13,642 | $106.0K |
| High Net Worth Advisory Group LLC | 2,500 | $19.0K |
| Cutler Group LP | 900 | $7.00K |
| TCI Wealth Advisors, Inc. | 846 | $7.00K |
| Smithfield Trust Co | 723 | $6.00K |
| State of Wyoming | 350 | $3.00K |
| Captrust Financial Advisors | 205 | $2.00K |